Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies

OBJECTIVES AND AIMS: Disease modifying therapies used in multiple sclerosis can decrease humoral response after COVID-19 vaccines. This problem must be adequately addressed because new variants evolve, and COVID-19 still poses a risk to patients with comorbidities and immunosuppression. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Baba, Cavid, Ozcelik, Sinem, Kaya, Ergi, Samedzada, Ulvi, Ozdogar, Asiye Tuba, Cevik, Sumeyye, Dogan, Yavuz, Ozakbas, Serkan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383952/
https://www.ncbi.nlm.nih.gov/pubmed/36037755
http://dx.doi.org/10.1016/j.msard.2022.104119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383952/
https://www.ncbi.nlm.nih.gov/pubmed/36037755
http://dx.doi.org/10.1016/j.msard.2022.104119

Ejemplares similares